Source-grounded facts extracted from OSR Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Mr. Hosun Euh was appointed as Director at OSR Holdings, Inc..
“On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.”
Dr. Rad Roberts was appointed as Director at OSR Holdings, Inc..
“On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.”
Dr. In Chul Chung was appointed as Director at OSR Holdings, Inc..
“On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.”
Dr. Steven G. Reed was appointed as Chairman of the Board at OSR Holdings, Inc..
“On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.”
OSR Holdings, Inc.: Filed Amended and Restated Certificate of Incorporation on February 13, 2023 (effective 2023-02-13).
“On February 13, 2023, the Company filed an Amended and Restated Certificate of Incorporation with the Secretary of the State of Delaware.”
OSR Holdings, Inc. entered into Underwriting Agreement with Chardan Capital Markets, LLC valued at $60.0 million (effective 2023-02-09).
“On February 9, 2023, Bellevue Life Sciences Acquisition Corp., a Delaware corporation (the “Company”), entered into an underwriting agreement by and between the Company and Chardan Capital Markets, LLC (“Chardan”), as representative of the several underwriters named therein (collectively, the “Underwriters”), a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference (the “Underwriting Agreement”), relating to the Company’s initial public offering (the “Offering”) of 6,000,000 units (the “Units”) at a price to the public of $10.00 per Unit.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.